<DOC>
	<DOCNO>NCT02175589</DOCNO>
	<brief_summary>The purpose study evaluate effect discontinuation colchicine treatment specific group asymptomatic FMF patient single mutation MEFV gene , clinical laboratory aspect .</brief_summary>
	<brief_title>Controlled Ceasing Colchicine Therapy Familial Mediterranean Fever ( FMF ) Patients With Single MEFV ( Mediterranean Fever ) Gene Mutation</brief_title>
	<detailed_description>The diagnosis FMF mainly clinical genetic test use confirm diagnosis . Even though disease autosomal recessive , FMF patient two recognizable MEFV mutation . The phenotype FMF patient varies accord genotype , show number study show patient one MEFV mutation milder disease even symptom . Some previously mention study show cease colchicine prophylaxis patient cause recurrence . So far , prospective control study test effect colchicine cessation group FMF patient . The investigator presume asymptomatic FMF patient single mutation stop regular colchicine treatment remain close follow-up . The purpose work : To examine effect colchicine cessation define group asymptomatic FMF patient single mutation MEFV gene . Methods study population : The work control prospective comparative study include FMF patient age 2-18 year . Patients include asymptomatic six month prior enter study regularly treat colchicine , normal serum level Serum Amyloid A ( SAA ) . The study group include patient single MEFV mutation stop colchicine therapy , control group include FMF continue regular colchicine treatment . Follow-up group include clinical laboratory ( serum SAA level ) evaluation . The study end point renewal colchicine : Any patient develops acute symptom FMF immediately invite rheumatology clinic medical examination . In addition , patient invite clinic 3 6 month begin study . At clinic visit ( schedule ) patient assess clinically laboratory ( serum SAA level ) . The study stop colchicine renew mention clinic visit patient diagnose classic FMF attack SAA level 10 mg / l. The importance study : If investigator conclude colchicine prophylaxis safely discontinue group FMF patient save treatment currently define treatment life .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Brucellosis</mesh_term>
	<mesh_term>Familial Mediterranean Fever</mesh_term>
	<mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Patients diagnose FMF base clinical criterion FMF patient diagnose least one common MEFV mutation assign study group . FMF patient staid colchicine treatment assign control group , regardless genotype . Patients continuous colchicine prophylactic treatment six month prior enter study . FMF patient free acute FMF symptom six month prior enter th study Patients include study normal serum level SAA ( 10 mg / l ) . Patients six month prior enter study continue classic FMF episodes despite continuous prophylactic colchicine Patients high level SAA ( 10 mg/l ) despite prophylactic colchicine treatment</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Familial Mediterranean Fever</keyword>
	<keyword>Monozygous</keyword>
	<keyword>MEFV</keyword>
	<keyword>Colchicine</keyword>
	<keyword>Serum Amyloid A</keyword>
</DOC>